Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Announcement from Embracer Group’s extra general meeting

The extra general meeting of Embracer Group AB (“Embracer” or the “Company”) was held today on 7 January 2022, and the following resolutions were passed by the meeting.Authorization for the board to issue shares for the acquisition of Asmodee The extra general meeting resolved, in accordance with the board of directors’ proposal, to authorize the board of directors during the period up until the next annual general meeting, on one or more occasions, to resolve to issue B shares, without preferential rights for the shareholders to be paid in cash, in kind and/or by way of set-off. A

Visma acquires cost recovery tool for Norwegian municipalities

Visma has acquired EnviDan Selvkost, a leading provider of a cost recovery solution for Norwegian municipalities. The acquisition further strengthens Visma’s position as a significant software provider for the public sector in Norway. EnviDan Selvkost is Norway's leading company in its field and has more than 70 percent of Norwegian municipalities on its customer list. Their solution is used by municipalities, waste companies and harbours to calculate fees for public services following legal requirements. “I am thrilled to welcome EnviDan Selvkost into the Visma family,” said Halvor

Corem signs four lease contracts

Corem has signed four lease contracts with a total annual contract value of SEK 38 million.In Stockholm, Corem has signed a 7-year contract with Cleanhouse for approximately 6,700 sq.m. in a property situated in Bromma and a 5-year contract with Region Stockholm for approximately 1,600 sq.m. in a property situated in the Globen area. In both cases, the tenants moved in during Q4 2021.In Stockholm, Corem has also signed a contract for extension of a lease contract with Bilia. The new lease is for 11 years, from Q1 2023, for approximately 11,000 sq.m. in a property situated in

Alligator Bioscience to Participate in Upcoming Investor Conferences

Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences: H.C. Wainwright BioConnect Conference, USLocation: Virtual Event Date: January 10-13 The presentation will be available online - January 10-13, 2022. Please visit the conference link to register and view the event. Redeye Fight Cancer Seminar - Outlook 2022Location: Virtual EventDate: Thursday,

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 6 - 7 JANUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

BERGENBIO - Mandatory notification of trade by Primary Insider

Bergen, Norway, 7 January 2022 – BerGenBio ASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.03 per share. After the transaction Mr. Olin holds 18,000 shares in BerGenBio ASA.   Please see the attached document for further details of the transaction. Contact:  ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com   This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (

myFC Lab Stories: The support system that keeps the fuel cells running

myFC Lab Stories is non-regulatory information from myFC's laboratory. The texts reflect the work that the company's researchers and developers carry out in the development of the patented technology. The numbers and data in this text are not to be considered as a forecast for future revenues. If the fuel cell is something of the heart in an application, then a Balance of Plant (BOP) is its nervous system. It is a surrounding set of technologies that supplies the fuel cells with the right amounts of fuel and takes care of them in every scenario.– Safety is another important aspect of a

Aptahem signs start up agreement with international clinical CRO for phase 1 studies with Apta-1

Aptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to prepare the upcoming phase 1 studies with Apta-1 and secure a timeslot to keep communicated timelines. As part of the SUA, CHDR will finalize the study protocol and prepare documentation to the authorities in collaboration with Aptahem.Aptahem is developing Apta-1 as an acute treatment to prevent organ and tissue damages in patients with sepsis or other

Hexagon Composites ASA initiates share buy-back program

The Board of Directors of Hexagon Composites ASA has resolved to initiate a share buy-back program which will be initiated today and be terminated before 18[th] January 2022 at the latest. The share buy-back program will be carried out on the basis of the authorization to acquire treasury shares granted by the Company's Annual General Meeting on 28 April 2021. The Company has been granted approval to acquire up to 1,500,000 shares, with a maximum aggregate outlay of NOK 50 million, under the share buy-back program for the purpose of fulfilling the Company's obligations under its

Commercial Update for OrderYOYO A/S - December 2021 ARR DKK 120m

Company Announcement No. 15-2022 OrderYOYO A/SInside Information Copenhagen, January 7, 2022 Financial Update 2021 · December 2021 ARR realized at DKK 120m compared to latest guidance of DKK 110 – 125m · December 2021 GMV realized at DKK 1,180m compared to latest guidance of DKK 1,100 – 1,400m. · No significant Covid-lockdown tailwind experienced in December 2021 vs high lockdown tailwind in December 2020 · Number of Restaurant Partners by end 2021 at 5,037 Net revenue and EBITDA for full year 2021 will be released following auditing. We will release our full year

BioStock: Curasight targets prostate cancer with theranostic approach

Danish biotech company Curasight is developing its theranostic platform to target and assess the aggressiveness of cancer tumours. The technology recently showed promising results in an investigator-initiated phase II trial in prostate cancer. In this article, BioStock takes a closer look at the prostate cancer diagnostics landscape to gain insight into how the company intends to position its product candidate uTRACE.Read the full article at biostock.se:https://www.biostock.se/en/2022/01/curasight-targets-prostate-cancer-with-theranostic-approach/This is a press release from BioStock -

InCoax wins additional order for 2 MSEK from US Fiber/LAN Operator

The year begins according to plan with an initial order from the US based Fiber/LAN Operator. The order will be supplied and invoiced during Q1 2022.The Operator currently has approximately half a million subscribers and is active in 19 US metropolitan areas of which InCoax is installed in nine of them. “The Fiber/LAN Operator follows up the stable order volume from 2021 with a new order under the recently signed Master Purchase Agreement (MPA)”, says Helge Tiainen, Head of Product Management, Marketing & Sales, InCoax Networks. The InCoax MoCA Access 2.5 platform is a cost-effective

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 6th January 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,913,005 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Nordea Bank Abp: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (BlackRock, Inc.)

Nordea Bank AbpStock exchange release – Major shareholder announcements7 January 2022 at 09.30 EET Nordea Bank Abp has on 6 January 2022 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has crossed the threshold of 5 per cent on 5 January 2022. The total number of shares and voting rights in Nordea Bank Abp is 3,965,561,160. Total positions of BlackRock, Inc. and its funds according to the notification: % of shares and

Concordium Blockchain Puts Backing Behind Newly Launched Crypto News Channel, Crypto Channel Direct

COPENHAGEN, Denmark –  Concordium, the layer 1 blockchain with an ID layer at the protocol level, has announced its sponsorship and backing of a new crypto-focused news channel: Crypto Channel Direct. Crypto Channel Direct (CCD) is an independent and impartial Youtube-based news show that will cover news and information from around the crypto sphere on a weekly basis with plans to ramp up productions in the future.  Concordium has come on as a key sponsor of the show and hopes to see it grow into a powerful and reputable news source, something that is much needed in the current space.

Arctic Bioscience to Present at H.C. Wainwright Bioconnect Conference

Arctic Bioscience, a biotech company developing and commercializing nutraceutical and pharmaceutical products based on the unique properties of bioactive marine compounds, will present at the US investment bank H.C. Wainwright’s Bioconnect Virtual Conference – discussing the company's phase IIb clinical trial, 2021 accomplishments, long term-strategy and 2022 priorities.H.C. Wainwright Bioconnect Conference Details: Date: January 10[th] from 13.00 CESTLink: Arctic Bioscience company presentation  Full event details:

Nordstjernan’s subsidiary Rosti acquires Plastic Components, Inc.

Nordstjernan’s wholly owned subsidiary Rosti has acquired 100 percent of the shares in the US company Plastic Components, Inc. (“PCI”). The acquisition of PCI strengthens Rosti’s global position in plastic injection molding and creates a platform for continued growth in North America. Rosti develops and manufactures injection-molded plastic components. The company’s offering includes container closures and lids for the food industry as well as manufacturing of components and complete products for selected consumer and industrial sectors. The company has manufacturing operations in China,

CFO Recruiter Suggests Adjusted TaaS Price and Margin Forecast

TaaS will significantly lower the production price of transport miles. Initially the pricing for TaaS miles will be set just below taxi prices and will likely disrupt the ride hailing business. As TaaS volume grows, price will be lowered to below the current cost per mile for privately owned cars. This may be in natural monopoly situation and if so, the TaaS price will stay on about that level. The potential monopolist will in this case make large profits. RethinkX and Tony Seba has illustrated expected cost and indicative consumer price, with the below graph which we further below

AstraZeneca and Neurimmune sign deal for NI006

07 January 2022 07:00 GMT AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006 Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition Alexion, AstraZeneca's Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid

Elekta to appoint Tobias Hägglöv as Chief Financial Officer

STOCKHOLM, January 7, 2022 – Elekta (EKTA-B.ST) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management positions at LEAX, Electrolux, SAS and Accenture. Gustaf Salford, CEO of Elekta, said: “I’m very pleased that Tobias will join Elekta. He brings strong expertise within finance and IT as well as broad experience from multinational companies. Elekta is fully focused on delivering on our ACCESS 2025 strategy and is

SynAct Pharma appoints Patrik Renblad as CFO

SynAct Pharma AB (“SynAct”) today announced that Patrik Renblad has been appointed Chief Financial Officer (CFO). Patrik Renblad joined the group in August 2021 as Vice President Finance and has since led the preparation for the upcoming listing of the Company at Nasdaq Main Market in Stockholm. Henrik Stage, who has been CFO of SynAct since 2016, will continue to support the Company as Special Advisor to the CEO.Patrik Renblad joined SynAct Pharma as Vice President Finance in August 2021 and has more than 20 years of experience from different roles in large and mid-sized pharmaceutical

There are no items matching the current filter
There are no more items matching the current filter
Back to top